Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Denmark / NCT05932472
Recruiting Phase 4

Randomized Comparison of Morning Versus Bedtime Administration of Aspirin: A Cardiovascular Circadian Chronotherapy (C3) Trial

NCT05932472 · tracked via the Priya Life Science Denmark tracker
Sponsor
Tor Biering-Sørensen
Phase
Phase 4
Started
2024-01-15
Last updated
2024-02-06

Condition(s) studied

AtherosclerosisCardiovascular DiseasesDrug Effect

Investigational drug(s) / intervention(s)

Aspirin →

Aspirin: Aspirin at currently prescribed dose

Study summary

Wide variability in the antiplatelet effects of aspirin may lead to recurrent thromboembolic events. Several pilot studies have suggested potential benefits of taking aspirin at bedtime rather than in the morning. The primary objective of this study is to examine whether aspirin administration at bedtime versus in the morning provides a superior reduction in the incidence of major adverse cardiovascular events among patients with or without established atherosclerotic cardiovascular disease, who are already taking aspirin.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age \>=18 years * Current chronic treatment with aspirin (as recorded in the Danish National Prescription Registry and confirmed by the participant via questionnaire) * Signed informed consent Exclusion Criteria: * There are no exclusion criteria for this trial

Primary outcome measure(s)

  • Composite of hospitalization for myocardial infarction, hospitalization for stroke, coronary revascularization, or cardiovascular death — Up to 3 years

Trial sites (1)

FacilityCityRegionStatus
Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte Hellerup Denmark Recruiting

More Tor Biering-Sørensen trials in Denmark

A Danish Pragmatic Randomized Trial of Nutritional Supplements in Heart Failure Recruiting
Electronic Letters to Improve Patient Activation in IHD: The NUDGE-IHD Trial Starting soon
Danish Pragmatic Randomized Trial to Evaluate the Effect of HeartLogic-Guided Management on Heart Failure Outcomes Recruiting
Randomized Comparison of Morning Versus Bedtime Administration of Statins: A Cardiovascular Circadian Chronotherapy (C3) Trial Starting soon
Copenhagen Heart Failure With Preserved Ejection Fraction Recruiting

Other trials for the same condition

Echocardiography in Men With Erectile Dysfunction Active, not recruiting
Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis Recruiting
Skeletal Maturation and Endocrine Health in Young Adults Enrolling by invitation
Repurposing Colchicine for Reduction of Residual Inflammatory Risk in Type 1 Diabetes Active, not recruiting
The Oxford Risk Factors And Non-Invasive Imaging Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05932472 on ClinicalTrials.gov ↗ ← All trials in Denmark